Tenax Secures Oral Levosimendan Supply, Extends Regulatory Deadline to 2035

summarizeSummary

Tenax Therapeutics has secured a long-term supply agreement for its oral levosimendan product and extended its U.S. regulatory approval deadline to 2035, significantly de-risking its product development.

check_boxKey Events · Product Development and Regulatory · TENX

• Supply Agreement for Oral Levosimendan

  Tenax entered a Supply Agreement with Orion Corporation for the manufacture and supply of its orally administered levosimendan product, with Orion designated as the primary supplier. This agreement covers forecasting, ordering, delivery, quality, pricing, and cost-sharing for manufacturing scale-up.

• Regulatory Approval Deadline Extended

  The Sixth Amendment to the License Agreement with Orion extends the date by which regulatory approval for the product must be obtained in the United States to December 31, 2035. This extension removes a key milestone-based termination right for either party.

• Long-Term Partnership Solidified

  The Supply Agreement has an initial term of five years from the first product delivery, with automatic three-year renewals, establishing a long-term manufacturing and supply partnership for a critical product.

auto_awesomeAnalysis · TENX · Life Sciences

This 8-K details two critical agreements with Orion Corporation. The Supply Agreement secures the manufacturing and supply chain for Tenax's orally administered levosimendan product, a key asset. Concurrently, the Sixth Amendment to their License Agreement extends the regulatory approval deadline in the U.S. to December 31, 2035. This significant extension provides the company with ample time to navigate clinical trials and regulatory processes, substantially reducing a major time-based risk for their product's path to market.